Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules

Acute severe ulcerative colitis (ASUC) is a medical emergency which occurs in about 20%–30% of patients with ulcerative colitis during their lifetime, and does carry a mortality risk of 1%. The management of inflammatory bowel diseases has evolved with changes in objective patient monitoring, as wel...

Descripción completa

Detalles Bibliográficos
Autores principales: Verdon, Christine, Bessissow, Talat, Lakatos, Peter L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947608/
https://www.ncbi.nlm.nih.gov/pubmed/31817972
http://dx.doi.org/10.3390/jcm8122169
_version_ 1783485590225813504
author Verdon, Christine
Bessissow, Talat
Lakatos, Peter L.
author_facet Verdon, Christine
Bessissow, Talat
Lakatos, Peter L.
author_sort Verdon, Christine
collection PubMed
description Acute severe ulcerative colitis (ASUC) is a medical emergency which occurs in about 20%–30% of patients with ulcerative colitis during their lifetime, and does carry a mortality risk of 1%. The management of inflammatory bowel diseases has evolved with changes in objective patient monitoring, as well as the availability of new treatment options with the development of new biological and small molecules; however, data is limited regarding their use in the context of ASUC. This review aims to discuss the emerging data regarding biologicals and small molecules therapies in the context of ASUC.
format Online
Article
Text
id pubmed-6947608
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69476082020-01-13 Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules Verdon, Christine Bessissow, Talat Lakatos, Peter L. J Clin Med Review Acute severe ulcerative colitis (ASUC) is a medical emergency which occurs in about 20%–30% of patients with ulcerative colitis during their lifetime, and does carry a mortality risk of 1%. The management of inflammatory bowel diseases has evolved with changes in objective patient monitoring, as well as the availability of new treatment options with the development of new biological and small molecules; however, data is limited regarding their use in the context of ASUC. This review aims to discuss the emerging data regarding biologicals and small molecules therapies in the context of ASUC. MDPI 2019-12-08 /pmc/articles/PMC6947608/ /pubmed/31817972 http://dx.doi.org/10.3390/jcm8122169 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Verdon, Christine
Bessissow, Talat
Lakatos, Peter L.
Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules
title Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules
title_full Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules
title_fullStr Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules
title_full_unstemmed Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules
title_short Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules
title_sort management of acute severe colitis in the era of biologicals and small molecules
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947608/
https://www.ncbi.nlm.nih.gov/pubmed/31817972
http://dx.doi.org/10.3390/jcm8122169
work_keys_str_mv AT verdonchristine managementofacuteseverecolitisintheeraofbiologicalsandsmallmolecules
AT bessissowtalat managementofacuteseverecolitisintheeraofbiologicalsandsmallmolecules
AT lakatospeterl managementofacuteseverecolitisintheeraofbiologicalsandsmallmolecules

Ejemplares similares